Saturday 17 October 2026 Export VRCA’s income statement to Excel — free account

Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.6 million, up 370.2% from fiscal 2024. In the quarter to June 2026, revenue fell 53.9%, EPS fell 3,200.0%, free cash flow grew 7.63% and total debt fell 97.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.54 0.24 −6.35%

Follow VRCA

Alert me

Market cap: $64.9M
P/E: 0.0×
Fwd P/E: −3.8×
Dividend yield: —
F-score: 6/9
Altman Z: −6.71
Beneish M: 14.25
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 18.18

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	5	—	—	—	—	—	—	—	—	4	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 58.88%

Capital & Financial Ratios $m

Market Cap 64.93

Revenue 30.32

Net Income (31.18)

Free Cash Flow (13.35)

Net Debt (10.40)

Current Ratio 1.45

Debt/Equity 0.18

P/E ratio 0.00

Fwd P/E (3.82)

P/S ratio 2.49

P/B ratio 17.51

Past 5Y EPS Growth —

This Y EPS Growth (21.69%)

Next Y EPS Growth 34.55%

Next Y revenue growth (30.24%)

Next 5Y EPS Growth 8.78%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 10.84%

10-year low 10-year high

P/B against its own 10 years 91.86%

10-year low 10-year high

EV/Sales against its own 10 years 10.64%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	70	46	30	11
Receivables	4	0	5	11
Inventory	1	2	2	3
Other	—	—	—	2
	78	51	43	33

	2023	2024	2025	Q'26
Payables	2	2	2	2
ST’ Debt	—	13	—	—
Other	—	—	—	4
	17	29	16	22

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	57.93%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(5.59%)	(14.82%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	5	6	—	—	—
’25	3	13	14	5	36
’24	4	5	(2)	0	8
’23	0	0	3	2	5
’22	0	0	8	0	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(9)	—	—	—
’25	(13)	(10)	10	(5)	(18)
’24	(20)	(16)	(9)	(16)	(61)
’23	(5)	(5)	(15)	(15)	(39)
’22	(8)	(7)	2	(5)	(19)
’21	(11)	2	(11)	(9)	(28)
’20	(8)	(9)	(8)	(6)	(30)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(9)	—	—	—
’25	(13)	(10)	10	(5)	(18)
’24	(20)	(16)	(9)	(16)	(61)
’23	(5)	(5)	(15)	(15)	(39)
’22	(8)	(7)	2	(5)	(19)
’21	(11)	2	(11)	(9)	(29)
’20	(9)	(9)	(8)	(7)	(32)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.45)	(0.62)	—	—	—
’25	(1.00)	0.02	(0.03)	(0.57)	(1.68)
’24	(4.40)	(3.70)	(4.90)	(2.40)	(14.80)
’23	(1.50)	(2.40)	(5.40)	(5.30)	(14.80)
’22	(3.10)	(3.70)	0.02	(1.40)	(7.20)
’21	(0.40)	(4.30)	(4.70)	(3.50)	(13.00)
’20	(3.90)	(3.80)	(4.20)	(5.20)	(17.10)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	64.40	68.40	60.20	85.10	17.70	27.70	6.11	3.28	Analyst estimates 2026–2028 Powerpack
	High	—	—	232.90	186.70	176.00	184.20	98.50	86.95	114.10	9.82
People
People	Employees	—	11	16	17	29	38	22	100	71	76
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.32	0.41	0.05	0.11	0.47
Income, $m
Income, $m	Revenue	—	—	—	—	—	12	9	5	8	36
	Gross margin, %	—	—	0.00	0.00	0.00	100.00	91.97	85.44	63.79	90.33
	EBT	(2)	(4)	(21)	(28)	(43)	(35)	(24)	(67)	(77)	(18)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	(292.33)	(271.11)	(1,307.47)	(1,012.15)	(50.27)
	Net income	(2)	(4)	(21)	(28)	(43)	(35)	(24)	(67)	(77)	(18)
	Depreciation	—	—	0	0	0	1	1	1	1	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	4.44	2.64	1.13	1.46	3.34
	Earnings	(5.19)	(15.65)	(14.10)	(11.30)	(17.10)	(13.00)	(7.20)	(14.80)	(14.80)	(1.68)
	Cash flow	(4.37)	(16.08)	(12.19)	(11.01)	(12.08)	(10.20)	(5.46)	(8.51)	(11.76)	(1.65)
	Capex	0.00	0.00	(0.53)	(0.77)	(0.68)	(0.40)	(0.14)	(0.08)	0.00	0.00
	Free cash flow	(4.37)	(16.08)	(12.72)	(11.77)	(12.76)	(10.60)	(5.60)	(8.59)	(11.76)	(1.65)
	Book value	0.34	29.71	60.99	26.11	13.20	12.06	11.72	4.36	(1.90)	2.32
	Shares, m	0	0	1	2	2	3	3	5	5	11
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	0.00	10.89	60.26	4.79	2.49
	P/B	—	—	—	—	—	7.60	2.46	15.62	0.00	3.58
	EV/Sales	—	—	—	—	—	0.00	7.27	55.32	4.58	2.01
	EV/FCF	—	—	—	—	—	(7.64)	(3.43)	(7.28)	(0.57)	(4.00)
Cash, $m
Cash, $m	Operating cash flow	(2)	(5)	(18)	(27)	(30)	(28)	(19)	(39)	(61)	(18)
	Capex	—	—	(1)	(2)	(2)	(1)	0	0	0	—
	Free cash flow	(2)	(5)	(19)	(29)	(32)	(29)	(19)	(39)	(61)	(18)
Balance, $m
Balance, $m	Working capital	0	8	89	62	28	28	36	61	22	26
	Total debt	—	—	—	0	37	42	2	44	45	1
	Net debt	(1)	(9)	(90)	(62)	(28)	(29)	(33)	(26)	(2)	(30)
	Shareholders’ equity	0	8	89	65	33	33	40	20	(10)	25
Returns, %
Returns, %	ROA	(39.74)	(202.74)	(40.89)	(35.19)	(59.89)	(45.48)	(39.23)	(106.07)	(112.84)	(35.33)
	ROIC	0.00	0.00	0.00	(590.08)	(555.11)	(487.82)	(182.68)	0.00	0.00	0.00
	ROE	39.42	201.11	(50.12)	(36.53)	(87.13)	(106.97)	(67.42)	(224.08)	(1,546.58)	(240.35)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CSBR Champions Oncology, Inc.	$66.7M	— (loss-making)	— (loss-making)	+8.84% (above 0%: growing)	n/m	−198.74% (below 0%: shrinking)	50.54%	(2.69%)	Compare
OSTX OS Therapies Incorporated	$66.0M	— (loss-making)	—	—	n/m	−134.43% (below 0%: shrinking)	—	0.00%	Compare
HYFT MindWalk Holdings Corp.	$66.0M	— (loss-making)	— (loss-making)	+19.37% (above 0%: growing)	n/m	+9.79% (above 0%: growing)	58.58%	(159.86%)	Compare
NMAD Nomad Power Solutions, Inc.	$65.9M	— (loss-making)	—	—	n/m	−230.63% (below 0%: shrinking)	—	0.00%	Compare
XBIT XBiotech Inc.	$65.9M	— (loss-making)	— (loss-making)	−93.33% (below 0%: shrinking)	n/m	+25.25% (above 0%: growing)	0.00%	0.00%	Compare
SPRO Spero Therapeutics, Inc.	$65.8M	7.9×	4.2×	−95.61% (below 0%: shrinking)	n/m	+69.73% (above 0%: growing)	100.00%	0.00%	Compare
VRCA Verrica Pharmaceuticals Inc.	$64.9M	— (loss-making)	— (loss-making)	−53.85% (below 0%: shrinking)	n/m	+7.63% (above 0%: growing)	85.02%	(223.42%)
CING Cingulate Inc.	$63.8M	— (loss-making)	—	—	n/m	−24.28% (below 0%: shrinking)	0.00%	0.00%	Compare
FBIO Fortress Biotech, Inc.	$63.7M	0.6×	1.1×	+14.04% (above 0%: growing)	n/m	−115.37% (below 0%: shrinking)	67.18%	(53.46%)	Compare
Median of peers	$65.9M	—	—	+8.84%	—	−69.82%	54.56%	0.00%

All 614 Biotechnology stocks →

Verrica Pharmaceuticals Inc. (VRCA) key facts

Strength: Verrica Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.6 million, up 370.2% from fiscal 2024.
Verrica Pharmaceuticals Inc. (VRCA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VRCA traded at $3.54, a market capitalization of $64.9 million.
Return on equity was −240.4% and debt-to-equity 0.18.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −6.71 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.